INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Inogen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Inogen, Inc. ("Inogen" or "the Company") INGN for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Inogen overstated the total addressable market ("TAM") for its portable oxygen concentrators, while also misstating the basis for its TAM calculations. The Company claimed that sales growth was based on an effective salesforce, when the growth was actually based on deceptive tactics used on an elderly client base. The Company's domestic growth was inflated and eroding other areas of its business. In fact, very little of Inogen's sales were from the more stable Medicare market. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Inogen, investors suffered damages.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall, or Sherin Mahdavian, of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190503005503/en/